Literature DB >> 35582072

Contact dermatitis associated with wearable cardioverter-defibrillator.

Tasuku Kurokawa1, Takanori Arimoto1, Naoaki Hashimoto1, Kyoko Koyama1, Ken Watanabe1, Daisuke Kutsuzawa1, Shigehiko Kato1, Tetsu Watanabe1, Yoriko Yaguchi2, Tamio Suzuki2, Masafumi Watanabe1.   

Abstract

A 51-year-old man with dilated cardiomyopathy was resuscitated from ventricular fibrillation. Twenty-days after using a wearable cardioverter-defibrillator (WCD) contact dermatitis with itching was evident and consistent with the self-gelling defibrillation electrodes patch on the back. Itching was controlled with clobetasol propionate application. The WCD was continued until catheter ablation and device implantation. The contact dermatitis was completely recovered two weeks after discontinuing the WCD. Among 58 patients using the WCD, three (5.2%) complained about discomfort with the device, and two (3.4%) complained of itching. Only the patient presented here (1.7%) suffered from contact dermatitis with itching. Contact dermatitis is rarely observed in patients wearing a WCD but physicians should be aware of this complication to maintain WCD compliance. <Learning objective: Inappropriate wearing of a wearable cardioverter-defibrillator (WCD) is sometimes related to an unfortunate clinical course. WCD compliance is of paramount importance since wearing it correctly can prevent a life-threatening arrhythmia. Contact dermatitis is rarely observed in patients wearing a WCD but physicians should be aware of this complication to maintain WCD compliance.>.
© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Contact dermatitis; Wearable cardioverter-defibrillator

Year:  2021        PMID: 35582072      PMCID: PMC9091528          DOI: 10.1016/j.jccase.2021.10.011

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  6 in total

Review 1.  Wearable cardioverter-defibrillators: A review of evidence and indications.

Authors:  Christopher C Cheung; Jeffrey E Olgin; Byron K Lee
Journal:  Trends Cardiovasc Med       Date:  2020-03-12       Impact factor: 6.677

2.  Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Systematic Review and Meta-Analysis.

Authors:  Ahmad Masri; Ahmed M Altibi; Sebhat Erqou; Mohammad A Zmaili; Ala Saleh; Raed Al-Adham; Karam Ayoub; Moaaz Baghal; Laith Alkukhun; Amr F Barakat; Sandeep Jain; Samir Saba; Evan Adelstein
Journal:  JACC Clin Electrophysiol       Date:  2019-01-30

3.  Wearable Cardioverter-Defibrillator after Myocardial Infarction.

Authors:  Jeffrey E Olgin; Mark J Pletcher; Eric Vittinghoff; Jerzy Wranicz; Rajesh Malik; Daniel P Morin; Steven Zweibel; Alfred E Buxton; Claude S Elayi; Eugene H Chung; Eric Rashba; Martin Borggrefe; Trisha F Hue; Carol Maguire; Feng Lin; Joel A Simon; Stephen Hulley; Byron K Lee
Journal:  N Engl J Med       Date:  2018-09-27       Impact factor: 91.245

4.  Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD.

Authors:  Arthur M Feldman; Helmut Klein; Patrick Tchou; Srinivas Murali; W Jackson Hall; Donna Mancini; John Boehmer; Mark Harvey; M Stephen Heilman; Steven J Szymkiewicz; Arthur J Moss
Journal:  Pacing Clin Electrophysiol       Date:  2004-01       Impact factor: 1.976

5.  Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: Results from the prospective multicenter CRED-registry.

Authors:  Michael Weiss; Guido Michels; Frank Eberhardt; Wolfgang Fehske; Stefan Winter; Frank Baer; Yeong-Hoon Choi; Christian Albus; Daniel Steven; Stephan Baldus; Roman Pfister
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

6.  Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study.

Authors:  Korbinian Lackermair; Christoph G Schuhmann; Michaela Kubieniec; Lisa M Riesinger; Ina Klier; Thomas J Stocker; Stefan Kääb; Heidi L Estner; Stephanie Fichtner
Journal:  Biomed Res Int       Date:  2018-06-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.